ライフサイエンスコーパス: skeletal-related event

1 a skeletal-related event, and time to first skeletal-related event.

2 ed with a 31% decreased risk of developing a skeletal-related event.

3 te cancer, primarily to improve survival and skeletal related events.

4 delayed pain progression, and prevention of skeletal-related events.

5 irst skeletal-related event and incidence of skeletal-related events.

6 patients are at greatest risk of developing skeletal-related events.

7 Skeletal metastases may result in skeletal-related events.

8 ted that zoledronic acid reduces the risk of skeletal-related events.

9 eveloping bone metastases and, subsequently, skeletal-related events.

10 spinal cord compression are also considered skeletal-related events.

11 o, 0.40; P<0.001), and the time to the first skeletal-related event (16.7 vs. 13.3 months; hazard rat

12 roportional hazards models for time to first skeletal-related event and incidence of skeletal-related

13 minobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone m

14 and pain, the proportion of patients with a skeletal-related event, and time to first skeletal-relat

15 ree survival, time to castration resistance, skeletal-related events, and adverse effects.

16 multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyel

17 ients in the placebo group had experienced a skeletal-related event by data cutoff.

18 d the proportion of patients with at least 1 skeletal-related event by disease type, pain as assessed

19 preferable to ibandronic acid in preventing skeletal-related events caused by bone metastases.

20 the proportion of patients having at least 1 skeletal-related event (defined as clinical fracture, sp

21 Secondary endpoints were time to first skeletal-related event (defined as radiation therapy or

22 The proportions of skeletal-related events did not differ significantly bet

23 azard ratio, 0.35), the time until the first skeletal-related event (hazard ratio, 0.72), a complete

24 ared to zoledronic acid in the prevention of skeletal related events in men with bone metastases.

25 ated outcomes and delays occurrence of first skeletal-related event in chemotherapy-naive men with me

26 Median time to first skeletal-related event in the enzalutamide (n=800) and p

27 was also associated with a lower risk of any skeletal-related event in the subsets of patients with (

28 rtant because they decrease the incidence of skeletal-related events in many tumour types and can com

29 Osteoclast-targeted agents reduce skeletal-related events in mCRPC.

30 ve shown efficacy in preventing and delaying skeletal-related events in patients with a variety of so

31 he standard of care for reducing the risk of skeletal-related events in patients with bone lesions fr

32 Bisphosphonates prevent skeletal-related events in patients with metastatic brea

33 have been shown to decrease the incidence of skeletal-related events in patients with metastatic cast

34 idronate (PAM) is recommended for preventing skeletal-related events in patients with MM.

35 Median time to first skeletal-related events in the enzalutamide group was 31

36 nosed multiple myeloma for the prevention of skeletal-related events, irrespective of bone disease st

37 Skeletal-related events may result both from disease and

38 secondary endpoints, including occurrence of skeletal-related events, measures of pain control, and p

39 h-related quality of life (HRQoL), pain, and skeletal-related events observed during this trial.

40 ity endpoint was the frequency and timing of skeletal-related events over 96 weeks, analysed using a

41 ion, skeletal morbidity rate (mean number of skeletal-related events per year), and, in a subset of 5

42 We assessed data for pain control and skeletal-related events prospectively collected as part

43 ival improved independently of prevention of skeletal-related events, showing that zoledronic acid ha

44 Overall survival (OS) and skeletal-related event (SRE) data have been reported for

45 was proportion of patients with at least one skeletal-related event (SRE), defined as pathologic frac

46 endpoints were progression-free survival and skeletal-related event (SRE).

47 gesic use, the proportion of patients with a skeletal-related event (SRE; defined as pathologic fract

48 edronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced

49 , patients experiencing one or more on-study skeletal-related events (SRE), and safety were also eval

50 Total skeletal related events (SREs), including surgery for pa

51 Zoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-re

52 and risedronate) and treatment/prevention of skeletal-related events (SREs) in multiple myeloma and b

53 th zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast c

54 l and economic burden of bone metastasis and skeletal-related events (SREs) in prostate cancer, and d

55 Purpose Skeletal-related events (SREs) such as pathologic fractu

56 ZOL significantly reduced skeletal-related events (SREs), and improved progression

57 Denosumab and radium-223 reduce the risk of skeletal-related events (SREs), but only radium-223 impr

58 atient: prolongation of life or reduction in skeletal-related events (SREs).

59 s with bone metastases to reduce the risk of skeletal-related events (SREs).

60 sion-free survival (CPFS) (pain progression, skeletal-related events [SREs], or death) and cost-effec

61 ledronic acid group had a lower incidence of skeletal-related events than did those in the clodronic

62 pulation, median time to occurrence of first skeletal-related event was significantly longer with abi

63 80) with zoledronic acid; the rate ratio for skeletal-related events was 1.148 (95% CI 0.967-1.362).

64 Annual rates of skeletal-related events were 0.499 (95% CI 0.454-0.549)

65 mide, are shown to decrease the incidence of skeletal-related events, whereas the radiopharmaceutical

66 We measured time to first occurrence of skeletal-related events, which we defined as pathologica

67 12-week dosing group experienced at least 1 skeletal-related event within 2 years of randomization (

68 one therapy; and whether they had a previous skeletal-related event within the last 3 months or had p